vinpocetine has been researched along with 2019 Novel Coronavirus Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Butakova, JS; Parshin, MS; Samartsev, IN; Zhivolupov, SA | 1 |
| Abdelmageed, N; Ahmed, M; El-Banna, HA; El-Zorba, HY; Ghallab, A; Haridy, M; Hassan, R; Morad, OA; Morad, SAF; Seddek, AL; Twafik, WA | 1 |
2 other study(ies) available for vinpocetine and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
[The open observational study of aceclofenac and vinpocetine effectiveness and tolerability in treatment of patients with chronic cerebrovascular disease after COVID-19 (AQUA study)].
Topics: Aged; Cerebrovascular Disorders; COVID-19; COVID-19 Drug Treatment; Diclofenac; Female; Humans; Male; Middle Aged; Post-Acute COVID-19 Syndrome; Vinca Alkaloids | 2021 |
Vinpocetine protects against chloroquine-induced cardiotoxicity by mitigating oxidative stress.
Topics: Animals; Cardiotoxicity; Chloroquine; COVID-19; COVID-19 Drug Treatment; Hydroxychloroquine; Mice; Oxidative Stress; SARS-CoV-2 | 2023 |